New PET scan tracer could reveal hidden cancer markers

NCT ID NCT06383598

Recruiting now Diagnosis Sponsor: Hua Zhu Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new radioactive tracer called [68Ga]Ga-THP-PDL1-3 for PET/CT scans in 50 adults with solid tumors. The goal is to see if it can safely and accurately show PD-L1 levels in tumors, which may help doctors personalize cancer treatment. Participants will receive both the new tracer and a standard FDG scan. The study focuses on safety, image quality, and radiation dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: [68Ga]Ga-THP-PDL1-3 (a radioactive tracer for PET scans)
What this could lead to: If successful, this could provide a non-invasive way to see PD-L1 levels in tumors, helping doctors choose the right treatments and monitor response without repeated biopsies.
What could go wrong: This is a very early, small pilot study (50 people) focused on safety and feasibility, not on treatment outcomes. The tracer may not reliably reflect PD-L1 changes, and results may not apply to all cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, 100142, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.